Boston Scientific (NYSE:BSX) Given New $77.00 Price Target at Needham & Company LLC

Boston Scientific (NYSE:BSX) had its price target cut by Needham & Company LLC from $97.00 to $77.00 in a research note released on Thursday, Marketbeat Ratings reports. They currently have a buy rating on the medical equipment provider’s stock.

A number of other research analysts also recently commented on BSX. Raymond James Financial reaffirmed an “outperform” rating and set a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. BTIG Research lowered their target price on shares of Boston Scientific from $90.00 to $80.00 and set a “buy” rating for the company in a report on Wednesday. Truist Financial dropped their price target on shares of Boston Scientific from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Thursday. Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Finally, TD Cowen decreased their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $93.91.

Boston Scientific Price Performance

BSX stock opened at $65.89 on Thursday. The stock has a market capitalization of $97.93 billion, a price-to-earnings ratio of 27.57, a price-to-earnings-growth ratio of 1.03 and a beta of 0.78. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. Boston Scientific has a 52-week low of $59.38 and a 52-week high of $109.50. The stock’s fifty day simple moving average is $68.71 and its 200-day simple moving average is $86.02.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.68% and a net margin of 17.29%.The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same period in the prior year, the firm posted $0.75 earnings per share. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts expect that Boston Scientific will post 3.36 EPS for the current year.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.34% of the stock is owned by insiders.

Institutional Trading of Boston Scientific

Large investors have recently added to or reduced their stakes in the stock. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the second quarter worth about $26,000. Murphy & Mullick Capital Management Corp lifted its position in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares in the last quarter. Financial Consulate Inc. acquired a new position in Boston Scientific during the 3rd quarter worth approximately $25,000. Swiss RE Ltd. purchased a new position in Boston Scientific in the 4th quarter worth approximately $26,000. Finally, United Community Bank boosted its holdings in Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 results beat estimates: Boston Scientific reported $5.20B in sales (up ~11.6%) and adjusted EPS of $0.80, topping consensus and showing broad demand across key cardiovascular franchises. This underpins the bullish view on organic growth drivers. Boston Scientific announces results for first quarter 2026
• Positive Sentiment: Market reaction / reset thesis: Some analysts and outlets framed the guidance cut as a constructive “reset” that creates a buying opportunity if management executes on long-term initiatives; that framing helped shares recover after the release. Boston Scientific Just Slashed Guidance and Wall Street Followed. Is the Pullback a Buying Opportunity?
• Neutral Sentiment: Analysts cut targets but largely kept bullish ratings: Multiple firms trimmed price targets (Truist, Baird, Needham, Jefferies, Barclays) while maintaining buy/outperform calls — signaling shorter-term caution but continuing confidence in longer-term upside. Boston Scientific Analysts Slash Their Forecasts After Q1 Earnings
• Neutral Sentiment: Broker commentary called the guidance cut “prudent” with a Q2 trough expected; analysts are modeling a weaker near term but still see recovery later in 2026. That supports mixed near-term sentiment but keeps longer-term forecasts intact. Boston Scientific 2026 Guidance Cut ‘Prudent,’ Q2 Trough Expected, RBC Says
• Negative Sentiment: Guidance cut: Management trimmed FY2026 EPS and revenue guidance below Street consensus and signaled softer near-term procedure volumes in some product lines — the primary reason for the re-rating and analyst target cuts. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
• Negative Sentiment: Legal risk and class-action notices: Multiple law firms have announced investigations and class-action filings alleging misstatements around procedure demand and disclosures; this raises potential litigation costs and short-to-medium-term headline risk. BOSTON SCIENTIFIC ALERT: Bragar Eagel & Squire, P.C. is Investigating Boston Scientific Corporation

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.